The role of TSH suppression during thyroid hormone therapy in the long-term follow-up of patients with differentiated thyroid cancer is an area of great uncertainty as few data exist on the risk of recurrence and death from thyroid cancer associated with varying serum TSH levels at 6–12 months post-surgery and radioactive iodine ablation. The gene discussed is TG; the disease is thyroid cancer.